Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the onychomycosis treatment market grown over the years?

The onychomycosis treatment market has seen significant growth and is projected to increase from $3.65 billion in 2024 to $3.92 billion in 2025, with a CAGR of 7.4%. Key factors contributing to this expansion include a higher prevalence of fungal infections, an aging population, greater public awareness, increasing disposable incomes, and the rising occurrence of onychomycosis.

What Is the forecasted market size and growth rate for the onychomycosis treatment market?

The onychomycosis treatment market is projected for steady expansion, reaching $5.09 billion by 2029 at a CAGR of 6.7%. Growth drivers include aging populations, telemedicine expansion, combination therapies, healthcare accessibility, lifestyle changes, and diabetes prevalence. Key trends involve dermatological advancements, drug delivery innovations, personalized treatments, topical treatment improvements, digital health solutions, and laser therapy.

Get your onychomycosis treatment market report here!

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What are the major factors driving growth in the onychomycosis treatment market?

The rising incidence of fungal infections is expected to propel the onychomycosis treatment market. Fungal infections, caused by various fungi, can affect different body parts, including nails. Onychomycosis treatments involve oral and topical antifungal medications to eliminate infections and restore nail health. In September 2023, the UK Health Security Agency reported 2,265 cases of yeast-related bloodstream infections in England in 2022, with an incidence rate increase from 3.8 to 4.0 per 100,000 people. The most common yeast species detected were Candida albicans (40%), Nakaseomyces glabratus (29%), and Candida parapsilosis (13%). This rise in fungal infections is driving the onychomycosis treatment market.

What key areas define the segmentation of the global onychomycosis treatment Market?

The onychomycosis treatment market covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types

2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy

3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

What are the top market players propelling the growth of the onychomycosis treatment industry?

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

What are the key trends shaping the future of the onychomycosis treatment market?

Leading businesses in the onychomycosis treatment market are striving for competitive advantage by developing and gaining federal approval for new products, like MOB-015. In June 2023, for instance, Moberg Pharma AB, a Swedish pharmaceutical firm, secured European Union approval for MOB-015, designed to treat mild to moderate nail fungal infections in adults. This green light by the European Union signifies the first global marketing permission for this innovative onychomycosis drug. Evidence from two Phase 3 trials that backed the approval of MOB-015 showed an enhanced mycological cure (76% vs. up to 42% for other comparables) and a remarkably higher total cure rate than the vehicle, with no serious side effects. The topical terbinafine formula, MOB-015, ensures efficient terbinafine concentrations reach the nail and nail bed without the systemic exposure risk that oral terbinafine treatment carries.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

What regions are dominating the onychomycosis treatment market growth?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Biopharmaceuticals Contract Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Mid-Size Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mid-size-pharmaceuticals-global-market-report

Generic Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: